CSF2 and respiratory failure: By neutralizing GM-CSF, GM-CSF autoantibodies in aPAP reduce pulmonary surfactant catabolism and lead to pathologic surfactant accumulation, which may contribute to respiratory failure and pulmonary fibrosis1–3.